Colorectal Cancer — Written Clinical Reasoning · Phys Written Answers

Prompt

DCE-style written reasoning for Colorectal Cancer.

SAQ 1 — Integrated plan (12 marks)

Prompt: Provide a prioritised problem list and management sequence for this presentation. [1] [2]

Model Answer

1. Frame and red flags (3 marks) [1]

State the working diagnosis/syndrome, acuity, and what would force emergency treatment now. [1] [2]

2. Discriminating assessment (3 marks) [2]

List the key history, examination and investigations that separate dangerous differentials from benign mimics. [1] [2]

3. Treatment sequence (4 marks) [1] [3]

Immediate stabilisation, disease-specific therapy, monitoring, and complications prevention. [1] [2] [3]

4. Follow-up and communication (2 marks) [2]

Disposition, safety-net advice, and who owns follow-up. [1] [2]

SAQ 2 — Exam trap defence (8 marks)

Prompt: Name two high-yield traps in Colorectal Cancer and how you avoid them. [1] [2]

Model Answer

Trap one: delayed escalation of a high-risk feature — avoid by explicit red-flag checklist. [1]

Trap two: therapy mismatched to mechanism — avoid by confirming the discriminating test before escalating treatment. [2] [3]

References

[1]Marmo R, Venezia L, Galeazzi F, Cannizzaro R, et al. Programme-level determinants of participation in colorectal cancer screening in Italy: a national cross-sectional study BMC Public Health, 2026.PMID 42469726
[2]Laforce-van Lierop LMA, Dang R, Narula N, Ingram RJM, et al. The VISION-AI Trial: protocol for a pragmatic randomized controlled non-inferiority trial comparing artificial intelligence-guided colonoscopy to pancolonic chromoendoscopy for neoplasia detection in adults with colorectal inflammatory bowel disease BMC Gastroenterol, 2026.PMID 42469662
[3]Zhen J, Dong M, Li Y, Cao B, et al. Human salivary microbiome as a potential non-invasive biomarker for early-onset colorectal cancer screening: a prospective study BMC Microbiol, 2026.PMID 42469627
[4]Lu TF, Shih YH, Chen YF, Fan CT, et al. Association of Hormone Therapy with Long-Term Outcomes After Chemoradiation for Locally Advanced Cervical Cancer Am J Obstet Gynecol, 2026.PMID 42468866
[5]Raja NP, Kandagari N Neoadjuvant Imatinib Therapy in Rectal Gastrointestinal Stromal Tumors: A Comprehensive Narrative Review of Tumor Downsizing, Sphincter Preservation, Transanal Surgical Platforms, Functional Outcomes, and Survival J Gastrointest Cancer, 2026.PMID 42467291
[6]Buali HF, Al Shaibani A, Farouqi US, Abushloa T, et al. Prostate Cancer Screening: Current Controversies and Future Directions Cureus, 2026.PMID 42465149
[7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
[8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922

SAQ 1 — Integrated plan (12 marks)

Prompt: Provide a prioritised problem list and management sequence for this presentation. [1] [2]

Model Answer

1. Frame and red flags (3 marks) [1]

State the working diagnosis/syndrome, acuity, and what would force emergency treatment now. [1] [2]

2. Discriminating assessment (3 marks) [2]

List the key history, examination and investigations that separate dangerous differentials from benign mimics. [1] [2]

3. Treatment sequence (4 marks) [1] [3]

Immediate stabilisation, disease-specific therapy, monitoring, and complications prevention. [1] [2] [3]

4. Follow-up and communication (2 marks) [2]

Disposition, safety-net advice, and who owns follow-up. [1] [2]

SAQ 2 — Exam trap defence (8 marks)

Prompt: Name two high-yield traps in Colorectal Cancer and how you avoid them. [1] [2]

Model Answer

Trap one: delayed escalation of a high-risk feature — avoid by explicit red-flag checklist. [1]

Trap two: therapy mismatched to mechanism — avoid by confirming the discriminating test before escalating treatment. [2] [3]

References

[1]Marmo R, Venezia L, Galeazzi F, Cannizzaro R, et al. Programme-level determinants of participation in colorectal cancer screening in Italy: a national cross-sectional study BMC Public Health, 2026.PMID 42469726
[2]Laforce-van Lierop LMA, Dang R, Narula N, Ingram RJM, et al. The VISION-AI Trial: protocol for a pragmatic randomized controlled non-inferiority trial comparing artificial intelligence-guided colonoscopy to pancolonic chromoendoscopy for neoplasia detection in adults with colorectal inflammatory bowel disease BMC Gastroenterol, 2026.PMID 42469662
[3]Zhen J, Dong M, Li Y, Cao B, et al. Human salivary microbiome as a potential non-invasive biomarker for early-onset colorectal cancer screening: a prospective study BMC Microbiol, 2026.PMID 42469627
[4]Lu TF, Shih YH, Chen YF, Fan CT, et al. Association of Hormone Therapy with Long-Term Outcomes After Chemoradiation for Locally Advanced Cervical Cancer Am J Obstet Gynecol, 2026.PMID 42468866
[5]Raja NP, Kandagari N Neoadjuvant Imatinib Therapy in Rectal Gastrointestinal Stromal Tumors: A Comprehensive Narrative Review of Tumor Downsizing, Sphincter Preservation, Transanal Surgical Platforms, Functional Outcomes, and Survival J Gastrointest Cancer, 2026.PMID 42467291
[6]Buali HF, Al Shaibani A, Farouqi US, Abushloa T, et al. Prostate Cancer Screening: Current Controversies and Future Directions Cureus, 2026.PMID 42465149
[7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
[8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922